Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of “Hold” by Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have been given an average recommendation of “Hold” by the nine analysts that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $31.8333.

STRO has been the subject of several research reports. Citizens Jmp upgraded Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price objective for the company in a research note on Tuesday, January 20th. Wall Street Zen cut Sutro Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. HC Wainwright increased their price objective on Sutro Biopharma to $10.00 and gave the company a “neutral” rating in a research note on Monday, December 22nd. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sutro Biopharma in a report on Wednesday, December 17th. Finally, Citigroup raised shares of Sutro Biopharma to an “outperform” rating in a report on Tuesday, January 20th.

Institutional Trading of Sutro Biopharma

Hedge funds have recently bought and sold shares of the business. Invesco Ltd. boosted its holdings in shares of Sutro Biopharma by 137.8% during the 1st quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock worth $60,000 after purchasing an additional 53,390 shares during the last quarter. AQR Capital Management LLC lifted its position in Sutro Biopharma by 1,052.8% during the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock worth $859,000 after buying an additional 1,206,330 shares in the last quarter. Strs Ohio acquired a new position in Sutro Biopharma during the first quarter worth $99,000. Vanguard Personalized Indexing Management LLC boosted its stake in Sutro Biopharma by 174.8% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 60,617 shares of the company’s stock worth $43,000 after buying an additional 38,561 shares during the last quarter. Finally, CWM LLC grew its holdings in Sutro Biopharma by 73.2% in the 2nd quarter. CWM LLC now owns 56,657 shares of the company’s stock valued at $40,000 after buying an additional 23,941 shares in the last quarter. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Stock Performance

NASDAQ:STRO opened at $15.64 on Tuesday. The company has a fifty day moving average of $10.72 and a two-hundred day moving average of $9.58. The stock has a market capitalization of $133.10 million, a PE ratio of -0.60 and a beta of 1.52. Sutro Biopharma has a fifty-two week low of $5.23 and a fifty-two week high of $21.25.

Sutro Biopharma (NASDAQ:STRO) last announced its earnings results on Thursday, November 6th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.25). Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%. The company had revenue of $9.69 million during the quarter, compared to analyst estimates of $10.14 million. Research analysts forecast that Sutro Biopharma will post -2.92 earnings per share for the current year.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.